metricas
covid
Buscar en
Medicina de Familia. SEMERGEN
Toda la web
Inicio Medicina de Familia. SEMERGEN Evaluación del grado de control de los rastornos lipídicos en los pacientes di...
Journal Information
Vol. 28. Issue 11.
Pages 610-614 (December 2002)
Share
Share
Download PDF
More article options
Vol. 28. Issue 11.
Pages 610-614 (December 2002)
Full text access
Evaluación del grado de control de los rastornos lipídicos en los pacientes diabéticos ipo 2 en una Zona Básica de Salud
Visits
3233
S. García de Franciscoa,
Corresponding author
saragdf@wanadoo.es

Correspondencia: S. García de Francisco. Av. Juan Andrés 44, 2°D. 28035 Madrid.
, M. Taboada Taboadaa, A. García de Franciscob, J. de las Heras Mosteiroa
a Centro de Salud. Fuencarral. Madrid
b Centro de Salud. Alameda de Osuna. Madrid
This item has received
Article information
Objetivos

. Analizar el estado actual del manejo de los trastornos lipídicos en los pacientes con diabetes mellitus tipo 2 de una Zona Básica de Salud y evaluar el grado de control sobre los mismos.

Métodos

. Se trata de un estudio observacional descriptivo transversal realizado en un Centro de Atención Primaria urbano en el que han participado todos los pacientes pertenecientes al Equipo de Atención Primaria, registrados en el último año en el programa OMI-AP como diabéticos tipo 2 con dislipidemias, siendo un total de 895. A través de la historia clínica informatizada y la histórica, se obtienen los datos de las variables edad, sexo, índice de masa corporal, HbA1c, colesterol total, colesterol HDL, colesterol LDL, triglicéridos, tensión arterial sistólica, diastólica, hábito tabáquico y tratamiento hipolipidemiante.

Resultados

. De una muestra de 146 pacientes, un 70,5% eran mujeres y con una edad media de 69,5±9,3 años. Tras un seguimiento medio tanto de la diabetes como de la dislipidemia de más de 7 años, la mayoría presentaba mal control de los trastornos lipídicos, así como de la diabetes y tensión arterial.

Conclusiones

. Sólo un 11,6% de los pacientes muestran un control adecuado, por ello es fundamental reforzar el seguimiento y tratamiento de los trastornos lipídicos en los pacientes diabéticos, tratándolos con la misma intensidad que los pacientes con cardiopatía para lograr disminuir el riesgo cardiovascular a corto y largo plazo.

Palabras clave:
diabetes mellitus
dislipidemia
colesterol
triglicéridos
colesterol LDL
colesterol HDL
Objectives

. To analyze the present status of the treatment of lipid disorders in type 2 diabetes mellitus patients from a basic health care zone and assess their degree of control.

Methods

. This is a cross-over descriptive observational study carried out in an urban Primary Health Care Center in which all the patients belonging to the Primary Health Care Teams, registered in the last year of the OMI-AP (organization and computing management of primary care) program as type 2 diabetics with dyslipemias, participated, the total being 895.

Based on the computerized clinical record and the clinical history, data is obtained on the variables of age, gender, BMI, HbA1c, total cholesterol, cholesterol HDL, cholesterol LDL, triglycerides, SBP, DBP, smoking habit and lipid lowering drug treatment.

Results

. A total of 70.5% out of a sample of 146 patients were women whose mean age was 69.5±9.3 years. After a mean follow-up of both the diabetes as well as the dyslipemia of more than 7 years, most presented poor control of the lipid disorders as well as of their diabetes and BP.

Conclusions

. Only 11.6% of the patients showed adequate control, thus it is essential to reinforce the follow-up and treatment of the lipid disorders in diabetic patients, treating them with the same intensity as patients with heart disease to be able to decrease the short and long term cardiovascular risk.

Key words:
diabetes mellitus
dyslipemia
cholesterol
triglycerides
cholesterol LDL
cholesterol HDL
Full text is only aviable in PDF
Bibliografía
[1.]
C. Sempos, J. Cleeman, M. Carroll, C. Johnson, P. Bachorik, D. Gordon, et al.
Prevalence of high blood cholesterol among US adults.
JAMA, 269 (1993), pp. 3009-3014
[2.]
R. Carmena, J.F. Ascaso, J.T. Real.
Dislipemia diabética.
Clin Invest Arteriosclerosis, 11 (1999), pp. 323-329
[3.]
K. Pyölärä, M. Laakso, M. Uusitupa.
Diabetes and atherosclerosis: an epidemiologic view.
Diabetes Metab Rev, 3 (1987), pp. 463-524
[4.]
S. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso.
Mortalidad por cardiopatía coronaria en pacientes con diabetes tipo 2 y en individuos no diabéticos con o sin infarto de miocardio previo.
N Engl J Med, 339 (1998), pp. 229-234
[5.]
M.P. Stern, J.K. Patterson, S.M. Haffner, H.P. Hazuda, B.D. Mitchell.
Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey.
JAMA, 262 (1989), pp. 360-364
[6.]
W.B. Kannel.
Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.
Am Heart J, 110 (1985), pp. 1100-1107
[7.]
UKPDS Group: UK Prospective Diabetes Study 6.
Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors.
Diabetes Res, 13 (1990), pp. 1-11
[8.]
Gerber, J. Alan.
Diabetes and heart disease: a new estrategy for managing lipid disorders.
Geriatrics, 48 (1993), pp. 34-41
[9.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP).
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II).
JAMA, 269 (1993), pp. 3015-3023
[10.]
D. Wood, G. De Backer, O. Faergeman, K. Pyörälä.
toghether with members of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the second Joint Task Force of the joint European Societies on coronary prevention.
Eur Heart J, 19 (1998), pp. 1434-1503
[11.]
S.M. Grundi.
Primary prevention of coronary heart disease. Integrating risk assesment with intervention.
Circulation, 100 (1999), pp. 988-998
[12.]
P.B. George, K.J. Tobin, R.A. Corpus, W.H. Devlin, W.W. O'Neill.
Treatment of cardiac risk factors in diabetics patients: How well do we follow the guidelines?.
Am Heart J, 142 (2001), pp. 857-863
[13.]
S.I. McFarlane, S.J. Jacober, N. Winer, J. Kaur, J.P. Castro, M.A. Wui, et al.
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers.
Diabetes Care, 25 (2002), pp. 718-723
[14.]
C.E. Ezenwaka, N.V. Offiah.
Cardiovascular risk in obese and nonobese patients with type 2 diabetes in the West Indies.
J Biomed Sci, 8 (2001), pp. 314-320
[15.]
S. Janssens, F. Van der Worf.
Cardiology. Acute coronary syndromes: Virchow's triad revisited.
Lancet, 348 (1996), pp. 2
[16.]
A. Keys, C. Aravanis, H.W. Blackburn, F.S.P. Van Buchem, R. Burina, B.D. Djordjevic, et al.
Epidemmiological studies related to coronary heart disease: characteristics of men aged 40-59 in Seven Countries.
Acta Med Scand, 460 (1967), pp. 1-392
[17.]
W.B. Kannel, J.D. Neaton, worth Went, H.E. Thomas, J. Stamler, S.B. Hulley, M.O. Kielsberg.
Overall and coronary heart disease mortality rates in relation to major risk factors in 325, 348 men screened for the MRFIT. Multiple Risk Factor Trial.
Am Heart, 112 (1986), pp. 825-836
[18.]
J.F. Plehn, B.R. Davis, F.M. Sacks, J.L. Rouleau, M.A. Pfeifer, V. Bernstein, et al.
Reduction of stroke incidence after myocardial infarction with pravastatina. The Cholesterol and Recurrent Eventes (CARE).
Circulation, 99 (1999), pp. 216-223
[19.]
W.H. Herman, C.M. Alexander, J.R. Cook, S.J. Boccuzzi, T.A. Musliner, T.R. Pederson, et al.
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinaviam Simvastatin Study.
Diabetes Care, 22 (1999), pp. 1771-1778
[20.]
G. Steiner.
Lipid Intervention Trial in Diabetes.
Diabetes Care, 2 (2000), pp. 49-53
[21.]
Documento de Consenso: Dislipemia diabética.
Sociedad Española de Arteriosclerosis y la Sociedad Española de Diabetes.
Clin. Invest. Arteriosclerosis, 10 (1998), pp. 55-64
[22.]
I. Berenguer, P. Birules, B. Molina, B. Vidiella.
Cano, Santos T (GEDAPS). Guía para el tratamiento de la diabetes tipo 2 en la Atención Primaria. Tercera edición.
pp. 19
[23.]
A. Maiques, J. Vilaseca.
Variabilidad en la valoración del riesgo cardiovascular.
FMC, 7 (2000), pp. 611-628
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos